Endocrine signaling research
Sermorelin
Peptide di ricerca liofilizzato sulla segnalazione endocrina per la revisione dei sistemi
Sermorelin is a GHRH 1-29 analog studied as a classic pituitary GH-axis research reference.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesSolo per ricerca di laboratorio. Non per uso umano o veterinario. Non destinato a diagnosticare, trattare, curare, mitigare o prevenire malattie.
Conservare sigillato, freddo, asciutto e protetto dagli sbalzi di calore. Conferma lo stoccaggio specifico del prodotto all'arrivo.
Imballato per garantire la stabilità del transito con supporto per gli ordini disponibile per le rotte con clima caldo.
Batch-linked certificate support is available through the documentation desk.
Contesto di ricerca
Profilo di ricerca Sermorelin
Sermorelin is a 29-amino-acid analog corresponding to the active amino-terminal region of growth hormone-releasing hormone. It is used as a classic reference for pituitary GHRH-receptor signaling, stimulated GH release, endocrine responsiveness, and downstream IGF-1 measurements. Compared with CJC-1295 with DAC, sermorelin represents a shorter GHRH framework without the same half-life-extension design. Compared with ipamorelin and GHRP peptides, it acts through a different receptor pathway. Researchers generally select sermorelin when the study calls for a well-established GHRH 1-29 reference or a direct comparison of pituitary signaling across GHRH analogs and ghrelin-receptor secretagogues.
Meccanismo proposto
A synthetic GHRH(1-29) peptide that activates the pituitary GHRH receptor, increases cyclic AMP, and stimulates endogenous growth-hormone release from responsive somatotroph cells.
Effetti riportati negli studi
- Human diagnostic and pharmacology studies reported acute GH release and used the response to evaluate pituitary reserve.
- Downstream changes can include transient increases in GH and IGF-1-related markers when repeated exposure is studied.
- Responses vary with age, pituitary function, endogenous somatostatin tone, timing, and prior exposure.
Endpoint di ricerca comuni
GHRH receptor signaling, cyclic AMP, peak and integrated GH, IGF-1, pituitary responsiveness, age-related response, pharmacokinetics, and comparison with longer-acting GHRH analogs.
Evidenze e limiti
The GHRH stimulation mechanism is well characterized, including historical human diagnostic use. This does not establish therapeutic equivalence of a catalog product.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.